Table 1.
Baseline characteristics of patients
| Characteristic | All patients (N = 47)a |
|---|---|
| Age (years) | 73 (52–85) |
| Gender | |
| Female | 19 (40.4%) |
| Male | 28 (59.6%) |
| Histologic type | |
| Adenocarcinoma | 32 (68.1%) |
| Squamous cell carcinoma | 9 (19.1%) |
| Other | 6 (12.8%) |
| Tumor stage | |
| I | 5 (10.6%) |
| II | 2 (4.3%) |
| III | 9 (19.1%) |
| IV | 31 (66.0%) |
| M categoryb | |
| M0 | 16 (34.0%) |
| M1a | 8 (17.0%) |
| M1b | 3 (6.4%) |
| M1c, single organ | 3 (6.4%) |
| M1c, multi organs | 17 (36.2%) |
| Chemotherapy | |
| TKI-naïve | 43 (91.5%) |
| TKI-treated | 4 (8.5%) |
Other not otherwise specified, TKI tyrosine kinase inhibitor
aResults are expressed as median (range) or number (%)
bAccording to the 8th TMN edition, M1a indicates lung metastases or pleural/pericardial malignant effusion or nodules; M1b indicates a single metastatic lesion in a single distant organ; M1c indicates multiple lesions in a single organ or multiple lesions in multiple organs